Unusual gangliosidosis in emu (Dromaius novaehollandiae)

Bettina Freischütz, Akira Tokuda, Toshio Ariga, Alex J. Bermudez, Robert K Yu

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

A previous study has demonstrated an unusual gangliosidosis in emu that is characterized by the accumulation of gangliosides in the brain tissues with GM3 and GM1 predominating. To provide insight into this unique disorder of emu gangliosidosis, the current study focused on analysis of neutral glycosphingolipids and gangliosides from brain and liver tissues of affected birds and healthy controls. We found not only that the total lipid-bound sialic acid content was increased three- and fourfold in the affected brain and liver, respectively, but also that the ganglioside pattern was rather complex as compared with the control. The absolute ganglioside sialic acid content was significantly increased in the diseased tissues, with the highest elevation levels of GM3 (14-fold) and GM1 (ninefold) in the affected brain. Relative increases in content of these monosialogangliosides were also significant. GM2 was only detected in the affected brain, but not in normal controls. The neutral glycosphingolipid fraction showed accumulation of many oligosylceramides, with six- and 5.5-fold increases in lactosylceramide levels for brain and liver, respectively. The level of myelin-associated galactosylceramide (GalCer) in the brain was decreased to only 41% of that in the healthy control, whereas no difference was found in liver tissues from both groups. Besides GalCer, the brain content of sulfatide (cerebroside- sulfate esters), another myelin-associated glycolipid, decreased to only 16% of the control. The loss of myelin-associated GalCer and sulfatide strongly suggests demyelination in the affected emu brain. Our overall data are consistent with the presence of a unique form of sphingolipidosis in the affected emus, perhaps with secondary demyelination, and suggest a metabolic disorder related to total sphingolipid activator deficiency.

Original languageEnglish (US)
Pages (from-to)2070-2078
Number of pages9
JournalJournal of Neurochemistry
Volume68
Issue number5
StatePublished - May 1 1997
Externally publishedYes

Fingerprint

Gangliosidoses
Dromaiidae
Brain
Gangliosides
Galactosylceramides
Liver
Myelin Sheath
Neutral Glycosphingolipids
Tissue
Sulfoglycosphingolipids
Demyelinating Diseases
N-Acetylneuraminic Acid
Sphingolipidoses
Sphingolipids
Glycolipids
Birds
Esters

Keywords

  • Emu
  • Gangliosides
  • Gangliosidosis
  • Glycolipids
  • Neutral lipids
  • Sphingolipid activator proteins

ASJC Scopus subject areas

  • Biochemistry
  • Cellular and Molecular Neuroscience

Cite this

Freischütz, B., Tokuda, A., Ariga, T., Bermudez, A. J., & Yu, R. K. (1997). Unusual gangliosidosis in emu (Dromaius novaehollandiae). Journal of Neurochemistry, 68(5), 2070-2078.

Unusual gangliosidosis in emu (Dromaius novaehollandiae). / Freischütz, Bettina; Tokuda, Akira; Ariga, Toshio; Bermudez, Alex J.; Yu, Robert K.

In: Journal of Neurochemistry, Vol. 68, No. 5, 01.05.1997, p. 2070-2078.

Research output: Contribution to journalArticle

Freischütz, B, Tokuda, A, Ariga, T, Bermudez, AJ & Yu, RK 1997, 'Unusual gangliosidosis in emu (Dromaius novaehollandiae)', Journal of Neurochemistry, vol. 68, no. 5, pp. 2070-2078.
Freischütz B, Tokuda A, Ariga T, Bermudez AJ, Yu RK. Unusual gangliosidosis in emu (Dromaius novaehollandiae). Journal of Neurochemistry. 1997 May 1;68(5):2070-2078.
Freischütz, Bettina ; Tokuda, Akira ; Ariga, Toshio ; Bermudez, Alex J. ; Yu, Robert K. / Unusual gangliosidosis in emu (Dromaius novaehollandiae). In: Journal of Neurochemistry. 1997 ; Vol. 68, No. 5. pp. 2070-2078.
@article{8eed599c7b174b51ab9aad3a6f61c23e,
title = "Unusual gangliosidosis in emu (Dromaius novaehollandiae)",
abstract = "A previous study has demonstrated an unusual gangliosidosis in emu that is characterized by the accumulation of gangliosides in the brain tissues with GM3 and GM1 predominating. To provide insight into this unique disorder of emu gangliosidosis, the current study focused on analysis of neutral glycosphingolipids and gangliosides from brain and liver tissues of affected birds and healthy controls. We found not only that the total lipid-bound sialic acid content was increased three- and fourfold in the affected brain and liver, respectively, but also that the ganglioside pattern was rather complex as compared with the control. The absolute ganglioside sialic acid content was significantly increased in the diseased tissues, with the highest elevation levels of GM3 (14-fold) and GM1 (ninefold) in the affected brain. Relative increases in content of these monosialogangliosides were also significant. GM2 was only detected in the affected brain, but not in normal controls. The neutral glycosphingolipid fraction showed accumulation of many oligosylceramides, with six- and 5.5-fold increases in lactosylceramide levels for brain and liver, respectively. The level of myelin-associated galactosylceramide (GalCer) in the brain was decreased to only 41{\%} of that in the healthy control, whereas no difference was found in liver tissues from both groups. Besides GalCer, the brain content of sulfatide (cerebroside- sulfate esters), another myelin-associated glycolipid, decreased to only 16{\%} of the control. The loss of myelin-associated GalCer and sulfatide strongly suggests demyelination in the affected emu brain. Our overall data are consistent with the presence of a unique form of sphingolipidosis in the affected emus, perhaps with secondary demyelination, and suggest a metabolic disorder related to total sphingolipid activator deficiency.",
keywords = "Emu, Gangliosides, Gangliosidosis, Glycolipids, Neutral lipids, Sphingolipid activator proteins",
author = "Bettina Freisch{\"u}tz and Akira Tokuda and Toshio Ariga and Bermudez, {Alex J.} and Yu, {Robert K}",
year = "1997",
month = "5",
day = "1",
language = "English (US)",
volume = "68",
pages = "2070--2078",
journal = "Journal of Neurochemistry",
issn = "0022-3042",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Unusual gangliosidosis in emu (Dromaius novaehollandiae)

AU - Freischütz, Bettina

AU - Tokuda, Akira

AU - Ariga, Toshio

AU - Bermudez, Alex J.

AU - Yu, Robert K

PY - 1997/5/1

Y1 - 1997/5/1

N2 - A previous study has demonstrated an unusual gangliosidosis in emu that is characterized by the accumulation of gangliosides in the brain tissues with GM3 and GM1 predominating. To provide insight into this unique disorder of emu gangliosidosis, the current study focused on analysis of neutral glycosphingolipids and gangliosides from brain and liver tissues of affected birds and healthy controls. We found not only that the total lipid-bound sialic acid content was increased three- and fourfold in the affected brain and liver, respectively, but also that the ganglioside pattern was rather complex as compared with the control. The absolute ganglioside sialic acid content was significantly increased in the diseased tissues, with the highest elevation levels of GM3 (14-fold) and GM1 (ninefold) in the affected brain. Relative increases in content of these monosialogangliosides were also significant. GM2 was only detected in the affected brain, but not in normal controls. The neutral glycosphingolipid fraction showed accumulation of many oligosylceramides, with six- and 5.5-fold increases in lactosylceramide levels for brain and liver, respectively. The level of myelin-associated galactosylceramide (GalCer) in the brain was decreased to only 41% of that in the healthy control, whereas no difference was found in liver tissues from both groups. Besides GalCer, the brain content of sulfatide (cerebroside- sulfate esters), another myelin-associated glycolipid, decreased to only 16% of the control. The loss of myelin-associated GalCer and sulfatide strongly suggests demyelination in the affected emu brain. Our overall data are consistent with the presence of a unique form of sphingolipidosis in the affected emus, perhaps with secondary demyelination, and suggest a metabolic disorder related to total sphingolipid activator deficiency.

AB - A previous study has demonstrated an unusual gangliosidosis in emu that is characterized by the accumulation of gangliosides in the brain tissues with GM3 and GM1 predominating. To provide insight into this unique disorder of emu gangliosidosis, the current study focused on analysis of neutral glycosphingolipids and gangliosides from brain and liver tissues of affected birds and healthy controls. We found not only that the total lipid-bound sialic acid content was increased three- and fourfold in the affected brain and liver, respectively, but also that the ganglioside pattern was rather complex as compared with the control. The absolute ganglioside sialic acid content was significantly increased in the diseased tissues, with the highest elevation levels of GM3 (14-fold) and GM1 (ninefold) in the affected brain. Relative increases in content of these monosialogangliosides were also significant. GM2 was only detected in the affected brain, but not in normal controls. The neutral glycosphingolipid fraction showed accumulation of many oligosylceramides, with six- and 5.5-fold increases in lactosylceramide levels for brain and liver, respectively. The level of myelin-associated galactosylceramide (GalCer) in the brain was decreased to only 41% of that in the healthy control, whereas no difference was found in liver tissues from both groups. Besides GalCer, the brain content of sulfatide (cerebroside- sulfate esters), another myelin-associated glycolipid, decreased to only 16% of the control. The loss of myelin-associated GalCer and sulfatide strongly suggests demyelination in the affected emu brain. Our overall data are consistent with the presence of a unique form of sphingolipidosis in the affected emus, perhaps with secondary demyelination, and suggest a metabolic disorder related to total sphingolipid activator deficiency.

KW - Emu

KW - Gangliosides

KW - Gangliosidosis

KW - Glycolipids

KW - Neutral lipids

KW - Sphingolipid activator proteins

UR - http://www.scopus.com/inward/record.url?scp=0038856165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038856165&partnerID=8YFLogxK

M3 - Article

VL - 68

SP - 2070

EP - 2078

JO - Journal of Neurochemistry

JF - Journal of Neurochemistry

SN - 0022-3042

IS - 5

ER -